tci Medicare Compliance & Reimbursement - 2017 Issue 1
Industry Note: OIG Continues to Turn Up the Notch on Prescription Drug Offenders
Subscribe or sign in to view the full article.
Article Overview
This short industry note summarizes a federal enforcement update involving alleged prescription drug diversion and broader health care fraud concerns. It is relevant to providers, compliance teams, auditors, and anyone tracking OIG/DOJ enforcement trends tied to controlled substances and Medicare-related risk.
Why This Topic Matters
The article highlights continuing federal scrutiny of prescription drug abuse and diversion, which can affect compliance programs, risk monitoring, and provider behavior across health care settings.
What You Will Learn
- The enforcement themes emphasized by the Office of Inspector General and related federal agencies.
- How prescription drug diversion is being framed as a compliance and fraud issue.
- Which government agencies are involved in the referenced case update.
- The general context of a provider-focused prescription drug investigation.
Who Should Read This
- Medical coders
- Compliance officers
- Healthcare administrators
- Auditors
- Physicians
- Podiatry practices
- Revenue integrity professionals
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.


Quick, Current, Complete - www.findacode.com